PVLA Stock Analysis: Palvella Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.105m USD | 12M Return: 485.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 39.1M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing and commercializing therapies for serious and rare genetic skin diseases. Its lead product candidate, QTORIN rapamycin (a 3.9% anhydrous topical gel), is in a Phase 3 trial for microcystic lymphatic malformations and a Phase 2 trial for cutaneous venous malformations, with additional development in angiokeratomas and other mTOR-driven skin conditions. The company is also advancing QTORIN pitavastatin for disseminated superficial actinic porokeratosis (DSAP). Headquartered in Wayne, Pennsylvania, Palvella operates within the rare disease drug development segment, where companies frequently pursue orphan drug designation and rely on capital markets and partnerships to fund late-stage clinical trials prior to commercialization.
- Phase 3 results for QTORIN rapamycin in lymphatic malformations
- Additional pipeline indications expand mTOR-driven skin disease opportunity
- Cash runway and capital raises critical as clinical-stage biotech advances to NDA
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.14 > 0.02 and ΔFCF/TA 13.22 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.11 > 3% & CFO -29.1m > Net Income -49.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 28.88 > 1.5 & < 3 |
| Outstanding Shares: last quarter (13.1m) vs 12m ago 487.8% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -6.86 > 6 (EBIT TTM -45.6m / Interest Expense TTM 6.64m) |
| A: 0.96 (Total Current Assets 263.2m - Total Current Liabilities 9.12m) / Total Assets 263.8m |
| B: -0.57 (Retained Earnings -151.2m / Total Assets 263.8m) |
| C: -0.27 (EBIT TTM -45.6m / Avg Total Assets 171.6m) |
| D: 7.39 (Book Value of Equity 232.3m / Total Liabilities 31.4m) |
| Altman-Z'' = 10.42 = AAA |
As of July 08, 2026, the stock is trading at USD 145.70 with a total of 152,930 shares traded. Over the past week, the price has changed by -5.90%, over one month by +38.43%, over three months by +21.39% and over the past year by +485.14%.
Current recommended Stop Loss: 124.10 (which is 14.8% or 2.3 ATR below the current price).
Palvella Therapeutics has received a consensus analysts rating of 4.78. Therefore, it is recommended to buy PVLA.
- StrongBuy: 7
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 229.6 | 57.6% |
P/B = 8.533
Revenue TTM = 0.0 USD
EBIT TTM = -45.6m USD
EBITDA TTM = -45.6m USD
Long Term Debt = 375k USD (estimated: total debt 584k - short term 209k)
Short Term Debt = 209k USD (from shortTermDebt, last quarter)
Debt = 584k USD (from shortLongTermDebtTotal, last quarter) (leases 584k already included)
Net Debt = -232.3m USD (calculated: Debt 584k - CCE 232.9m)
Enterprise Value = 1.87b USD (2.10b + Debt 584k - CCE 232.9m)
Interest Coverage Ratio = -6.86 (Ebit TTM -45.6m / Interest Expense TTM 6.64m)
EV/FCF = -52.14x (Enterprise Value 1.87b / FCF TTM -35.9m)
FCF Yield = -1.92% (FCF TTM -35.9m / Enterprise Value 1.87b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 7.10 (Enterprise Value 1.87b / Total Assets 263.8m)
Interest Expense / Debt = 1.14k% (Interest Expense 6.64m / Debt 584k)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -36.0m (EBIT -45.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 18.08 (Total Current Assets 263.2m / Total Current Liabilities 14.6m)
Debt / Equity = 0.00 (Debt 584k / totalStockholderEquity, last quarter 232.3m)
Debt / EBITDA = 5.10 (negative EBITDA) (Net Debt -232.3m / EBITDA -45.6m)
Debt / FCF = 6.47 (negative FCF - burning cash) (Net Debt -232.3m / FCF TTM -35.9m)
Total Stockholder Equity = 86.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -28.73% (Net Income -49.3m / Total Assets 263.8m)
RoE = -56.87% (Net Income TTM -49.3m / Total Stockholder Equity 86.7m)
RoCE = -52.36% (EBIT -45.6m / Capital Employed (Equity 86.7m + L.T.Debt 375k))
RoIC = -14.13% (negative operating profit) (NOPAT -36.0m / Invested Capital 254.9m)
WACC = 5.65% (E(2.10b)/V(2.11b) * Re(5.65%) + (debt cost/tax rate unavailable))
Discount Rate = 5.65% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 185.3%
[DCF] Fair Price = unknown (Cash Flow -35.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.10 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.16 | Chg30d=+1.21% | Revisions=-36% | Analysts=12
EPS next Quarter (2026-09-30): EPS=-1.47 | Chg30d=+0.13% | Revisions=+0% | Analysts=12
EPS current Year (2026-12-31): EPS=-5.57 | Chg30d=+0.03% | Revisions=-44% | GrowthEPS=-50.0% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-6.82 | Chg30d=-2.04% | Revisions=-17% | GrowthEPS=-22.5% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -41% (up=7, down=19)